Bioray Biotech Co., Ltd (TPEX: 7561)
Health Care · Biotechnology · TW
NT$17.10
-8.31% today · -31.0% 1Y
Bioray Biotech Co., Ltd (TPEX: 7561) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.89M and employs 79 people.
Over the last twelve months the share price has lost 31.0%, trading between 16.25 and 32.10.
Tweenvest scores Bioray Biotech Co., Ltd across four factors: quality 75/100, value 56/100, growth 18/100, dividend 49/100. Its strongest factor is quality.
7561 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.89M
- Revenue (TTM)
- $6.51M
- P/E
- 26.27
- EPS
- 0.65
- Dividend yield
- 5.56%
- Beta (5Y)
- 0.10
- 52-week high
- NT$32.10
- 52-week low
- NT$16.25
- Avg volume (3M)
- —
- Shares outstanding
- 29.59M
- Employees
- 79
- Next earnings
- —
About Bioray Biotech Co., Ltd
Bioray Biotech Co., Ltd is dedicated to the innovation, manufacturing, and distribution of biological and health supplement products. The company's biological offerings span specialized functional probiotics, therapeutic fungi, and immune cell preparations. Additionally, Bioray Biotech extends its expertise to the field of cellular testing and preservation services. Founded in 1994, this Taiwanese firm is based in Pingtung.
- ISIN
- TW0007561B13
- Founded
- 2005
- Listed since
- Jul 27, 2020
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.40 | -1.65% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.29 | +0.01% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $149.00 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.77 | -0.38% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.75 | -1.18% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.70 | -7.01% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.